Prescribing information

This page/content is for Great Britain healthcare professionals only.

Pluvicto®▼ (lutetium [177Lu] vipivotide tetraxetan) is indicated for the treatment of adult patients with prostate-specific membrane antigen (PSMA)-positive metastatic castration-resistant prostate cancer (mCRPC) who have been treated with androgen receptor (AR) pathway inhibition and taxane-based chemotherapy or who are not medically suitable for taxanes.1

 

Contact us

To contact a member of the Novartis Pharmaceuticals UK Limited team, please click below to fill in the request form.

 

 

 

Icon of an arrow on the bulls-eye of a target. Show more.

Pluvicto mechanism of action

Pluvicto targets PSMA-positive cells, including prostate cancer cells.1

Show more about Pluvicto mechanism of action

 

Icon of a magnifying glass. Show more.

Safety profile

The efficacy and safety profile of Pluvicto + BSoC were assessed in the VISION trial.2

Show more on the safety profile

 

Icon representing administration of Pluvicto. Read more.

Dosing and administration

Pluvicto is a ready-to-use solution administered intravenously.1

Read more about dosing and administration

 

AR, androgen receptor; BSoC, best standard of care; mCRPC, metastatic castration-resistant prostate cancer; PSMA, prostate-specific membrane antigen.

References:

  1. Pluvicto® Great Britain Summary of Product Characteristics.
  2. Sartor O, et al. N Engl J Med 2021;385(12):1091–1103.
AAA-PSMA-UK-0658 | April 2024
×

Ask Speakers

×

Medical Information Request